Drug intelligence / Profile preview

NAL3210

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

NAL3210 is an antifungal nail lacquer under development by NAL Pharmaceutical Group for the treatment of onychomycosis (nail fungus). Formulated for topical administration, the product is designed to penetrate the nail plate to deliver the active antifungal agent to the underlying nail bed. It is currently in the preclinical stage of development and utilizes a lacquer-based delivery system to provide sustained contact with the infected nail tissue.

Other names: Antifungal Lacquer

Beyond the preview

Go deeper on NAL3210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL3210.

Explore the full profile